^
Association details:
| Biomarker: | JAK2 underexpression |
|---|---|
| Cancer: | Cutaneous Melanoma |
| Drug: | Inrebic (fedratinib) (JAK2 inhibitor, FLT3 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Mining database for the expression and gene regulation network of JAK2 in skin cutaneous melanoma
Published date:
03/29/2020
Excerpt:
JAK2 level was significantly correlated with the abundance of immune cells and the level of immune biomarkers. Low expression of JAK2 were resistant to QL-VIII-58, TL-1-85, Ruxolitinib, TG101348 and Sunitinib….Our results reveal the expression and gene regulation network of JAK2 in skin cutaneous melanoma, providing more evidences about the role of JAK2 in carcinogenesis.
DOI:
10.1016/j.lfs.2020.117600
